Evgen Pharma Share Discussion Threads

[stockhunters] 29/9/2020 07:54

dddd into new highs

evg will not be far behind

[moneymunch] 29/9/2020 06:50

There appear's to have been a massive percentage of share transfers over the last few months, is there an orderley accumualtion going on under the radar??? ;-)

[bumpa33] 28/9/2020 17:20

They’ll be some form of transfer mm I suspect...

[moneymunch] 28/9/2020 17:04

Another .5m trade at 11.30p late reported (16.54pm ), listed as a buy!!! Gla ;-)

[moneymunch] 28/9/2020 16:10

Yep, although on LSE the trade type is also listed, such as "Delayed", "Ordinary" and "Non protected portfolio, Single protected transaction" etc which denotes a trade between instituitions, and so as both are listed as Ordinary suggests a normal buy or sell transaction, and at 11.30p, both look like buys imho...Gl ;-)

[mesquida] 28/9/2020 15:40

With respect, LSE interpretations of trade types mean naff all. Ditto ADVFN. Both of them are simply judging trades to be buys ( or sells ) depending on whether the reported price is above ( or below ) the mid point at the time when the trade was executed. Surely at times you yourself have bought at below the mid price and then seen your trade reported as a sale ? !

[mesquida] 28/9/2020 14:52

Not sure that i agree with your theory that they were both buys, do you really think that the marketmakers would go short of 100,000 if they did not have a seller to match, and here we are several hours later and still no matching sale has appeared. No, in my opinion it is much more likely that these two marks are some sort of transfer between funds in the same management group.

[moneymunch] 28/9/2020 13:31

2 x .5m buys earlier....the accumulation continues....Gla ;-)

[bumpa33] 27/9/2020 20:48

Interesting line from our new mans Bio at Chronos...

“He has supervised over fifteen product launches in Europe and has completed numerous product and company acquisitions and divestments.“

[moneymunch] 27/9/2020 15:23

and Rochester , New York. ;-)

13/2/20

University of Rochester Collaboration

Evgen Pharma (Evgen) and The University of Rochester School of Medicine and Dentistry have entered into a Memorandum of Understanding to advance SFX-01 towards a clinical trial in chronic kidney disease (CKD).

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

Dr Stephen Franklin, CEO of Evgen Pharma, commented:

"We are delighted to be supporting the work of such a respected team and prestigious university. We very much hope the proposed trial will generate data demonstrating that SFX-01 could potentially improve the lives of patients suffering from CKD."

[moneymunch] 27/9/2020 15:17

As well as the status of SFX-01's patient trials , more news from Unversity of Dundee also expected. Gla ;-)


Active

Defining the Oxidative Stress-Related Mechanisms by which Activation of the Transcription Factor Nrf2 Arrests and Resolves Liver Fibrosis

Arthur, S., Dillon, J., Dinkova-Kostova, A., Hayes, J. & Henderson, C.

Medical Research Council

1/04/20 → 31/03/24

Project: Research


Funding


Medical Research Council (MR/T014644/1): £2,428,412.00


5/12/19

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.

With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation.

Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK.

Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."

16/7/20


Metabolic Associate steatohepatitis (MASH)

Metabolic associated fatty liver disease (MAFLD) is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population

10%-20% of those with MAFLD have MASH and 20-30% of MASH patients are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years

Professor John Dillon (University of Dundee) showed that activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigate against MASH and liver fibrosis.

MoU with the University of Dundee to supply SFX-01 for a potential clinical trial in MASH

Option to license the clinical data to enable subsequent development/commercialisation of SFX-01 in MASH and liver fibrosis

[bumpa33] 27/9/2020 12:21

So now we’re “active” again - from 01/08?

Let’s hope they’re conducting the trial better than they update their project info??!

Joking aside, great news.

[bocker01] 25/9/2020 14:24

Two months into it Money and a very significant sample size. Should see a meaningful update well before Christmas if not much much earlier. Maybe back to back with some news on the real big hitter, our breast cancer tumour stopper and reverser. Cheery news as this research has implications for all illnesses involving serious lung inflammation rather than just being Covid related.

[moneymunch] 25/9/2020 14:17

ps maybe the new CEO can provide an update on the status of the Covid-19 patient trials next week...Gla ;-)

[moneymunch] 25/9/2020 14:13

Interestingly enough , Active from 1st August 2020!!! ;-)


A randomized controlled trial of SFX-01 to improve clinical outcomes in COVID-19 patients (STAR-COVID)

Chalmers, James (Investigator)Dinkova-Kostova, Albena (Investigator)

Molecular and Clinical MedicineCellular Medicine

Overview

Project Details
Status
Active
Effective start/end date
1/08/20 → 31/07/21
Funding

LifeArc: £370,246.00

[notknowing] 25/9/2020 14:07

Any price targets here?

[on target] 25/9/2020 13:18

COVID trial now gone back to active..

[toffeeman] 25/9/2020 09:18

You may consider me to be a clueless Scouse git, but there is a difference between overdue trading updates which are not market sensitive and other event which are; only the latter require an RNS.

Have a lovely weekend MM

[toffeeman] 25/9/2020 08:50

If there was anything RNS-worthy, the company would be required to update the market, with or without a CEO.